Tuttle Capital Management’s Novavax NVAX Stock Holding History

Tuttle Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10,731	Closed	-$77.7K	–	62
2023 Q3	$77.7K	Buy	+10,731	New	+$85.7K	0.52%	42

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Tuttle Capital Management's NVAX Position: Q4 2023 in Review

Tuttle Capital Management sold out of Novavax (NVAX) in Q4 2023, closing a stake of 10,731 shares — an estimated $77.7K sold.

Tuttle Capital Management first reported a position in NVAX in Q3 2023 and held it in 1 quarter. The position peaked at $77.7K in Q3 2023. 199 funds tracked by Wall St. Rank hold NVAX as of Q4 2023.

Tuttle Capital Management reported no remaining Novavax position as of Q4 2023 after selling out during the quarter.
Tuttle Capital Management sold 10,731 Novavax shares in Q4 2023, an estimated $77.7K.
Tuttle Capital Management first reported a position in Novavax in Q3 2023 and held it in 1 quarter.
Tuttle Capital Management's Novavax position peaked at $77.7K in Q3 2023.
199 funds tracked by Wall St. Rank held Novavax as of Q4 2023.

Based on Tuttle Capital Management's 13F filing for Q4 2023, filed 10 Jan 2024.